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Four analogues of vitamin D, with an oxygen atom in the side chain skeleton were synthesized to determine 
whether their differentiation-inducing activity could be separated structurally from their activity to induce 
hypercalcemia. The order of the in vitro potency to reduce nitroblue tetrazolium in human myeloid leukemia 
cells (HL-60) was 22-oxa-la,25-(OH&D, > la,25-(OH)ZD, > 20-oxa-la,25-(OH)ZD, + 22-oxa-l a-(OH) 
D, > la-(OH)D, >20-oxa-la-(OH)D,. 22-Oxa-la,25-(OH),D, was also about IO-times more potent than 
1 c(,~S-(OH)~D, in suppressing proliferation and inducing differentiation of mouse myelomonocytic leukemia 
cells (WEHI-3), but the former was much weaker than the latter in inducing the release of ‘+%a from prela- 
beled fetal mouse calvaria. These results suggest that the differentiation-inducing activity of vitamin D com- 
pounds can be separated structurally from their activity to induce hypercalcemia. 
Vitamin D; la,25-Dihydroxy-22-oxavitamin D3; Differentiation-inducing activity; Bone-resorbing activity 
1. INTRODUCTION 
la,25-Dihydroxyvitamin Dj (1@,25-(OH)zDs), 
the active form of vitamin D3, has been known to 
regulate serum calcium levels by promoting in- 
testinal calcium transport and bone mineral 
mobilization. In 1981, Abe et al. [I] first 
demonstrated that 1~~,25-(OH)zD3 suppressed pro- 
liferation of mouse myeloid leukemia cells (Ml) 
and caused them to be differentiated into cells that 
are morphologically and functionally similar to 
mature monocyte-macrophages. Administration 
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of la-hydroxyvitamin DZ (1~(0H)D3), a synthetic 
analogue of l~u,25-(OH)2D3 active in anephric pa- 
tients, either with or without daunomycin con- 
siderably prolonged the survival time of leukemic 
mice inoculated with Ml cells [2,3]. But the con- 
centration of 1~~,25-(OH)zD3 in vitro required to 
induce maximal growth suppression and differen- 
tiation was 10 nM. This is about lOO-times higher 
than the physiological serum levels of 
1~~,25-(OH)2D3 [ 11. This prompted organic 
chemists to synthesize vitamin D analogues which 
are capable of potent differentiation-inducing ac- 
tivity without inducing hypercalcemia. They have 
synthesized numerous new derivatives of vitamin 
D3, but none of these has achieved the intended 
purpose [4-71. 
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In our laboratory, 4 interesting new derivatives 
of vitamin D3 have been synthesized for this pur- 
pose [8,9]. One of these is lcu-hydroxy-21-nor- 
20-oxavitamin D3 (20-oxa-la-(OH)D3). The sec- 
ond one is la,25-dihydroxy-21-nor-20-oxavita- 
min D3 (20-oxa-1@,25-(OH)zDj). In these two 
compounds the carbon atom at position 20 is 
replaced by oxygen. The third one is lcu-hydroxy- 
22-oxavitamin D3 (22-oxa-la-(OH)Dj) and the 
fourth is la,25dihydroxy-22-oxavitamin D3 
(22-oxa-l&,25-(OH)zDJ). In these two compounds 
the carbon atom at position 22 is replaced by oxy- 
gen. We report here that 22-oxa-la,25-(OH)2D3 is 
about IO-times more potent than lcu,25-(OH)2D3 in 
suppressing growth and inducing differentiation in 
vitro of human and mouse myeloid leukemia cells, 
but the former compound is much weaker than the 
latter in inducing the release of 4sCa from prela- 
beled fetal mouse calvaria. 
2. MATERIALS AND METHODS 
2.1. Cells and cell culture 
The human myeloid leukemia cell line HL-60 
and the murine myelomonocytic leukemia cell line 
WEHI- were kindly provided by Dr H. Hemmi, 
School of Medicine, and by Dr K. Kumagai, 
School of Dentistry, respectively, both at Tohoku 
University, Sendai, Japan. Both cell lines were 
cultured in RPMI-1640 medium supplemented 
with L-glutamine (0.29 mg/ml), Kanamycin 
(0.6 pug/ml) and 5% heat-inactivated fetal bovine 
serum at 37°C in a humidified atmosphere of 5% 
CO2 in air. 
2.2. Vitamin Dj derivatives 
lau,25-(OH)2D3 was purchased from Philips 
Duphar, Amsterdam, The Netherlands. la- 
(0H)Ds was synthesized in our laboratory. The 
new derivatives of vitamin D3: 20-oxa- 
la,25-(OH)zDs, 20-oxa-la-(OH)D3, 22-oxa- 
l~u,25-(OH)~D3 and 22-oxa-la-(OH)D3 (fig. l), 
were synthesized from dehydroepiandrosterone in 
our laboratory. The detailed synthesis procedures 
have been described [8,9]. These compounds were 
dissolved in absolute ethanol and the stock solu- 
tions were stored at -20°C. The final concentra- 
tion of ethanol in the culture medium was less than 
0.1070, which had no effect on the viability of these 
cells. 
2.3. Assessment of cell growth and differentiation 
of HL-60 and WEHI- 
To examine the effect of vitamin D3 compounds 
on cell growth, WEHI- cells (1 x 10’) were 
cultured for 5 days in 10 ml of culture medium 
containing vitamin D3 compounds. On each day, 
cells were harvested and the cell number was 
determined. 
Expression of phenotypes associated with dif- 
ferentiation was examined with the nitroblue 
tetrazolium (NBT)-reducing activity in HL-60 cells 
and with the phagocytic activity in WEHI- cells. 
To measure NBT-reducing activity, HL-60 cells 
(1 x 104/ml) were incubated for 20 min at 37°C in 
RPMI-1640 medium containing NBT (1 mg/ml) 
and 12-0-tetradecanoylphorbol-13-acetate (TPA, 
100 ng/ml). The number of cells containing for- 
mazan deposits was counted to determine the 
percentage of reacting cells [lo]. To measure 
phagocytic activity, WEHI- cells (1 x 105/ml) 
were incubated for 4 h at 37°C with 5 ~1 latex par- 
ticles (average diameter, 0.81 ,um; Difco) in PBS. 
After washing 3 times with PBS, the percentage of 
phagocytic cells was determined by counting [lo]. 
2.4. Measurement of bone-resorbing activity 
The bone-resorbing activity was measured as 
described [5]. In short, mice (ddy strain), 16 days 
pregnant, were injected intraperitoneally with 
25 ,uCi 45CaC12 (New England Nuclear, Boston, 
MA). One day later the calvaria was isolated and 
divided into paired halves. These were precultured 
for 1 day at 37°C in BGJb medium (Gibco) con- 
taining 0.1% BSA. Then each half-calvarium was 
cultured for 5 days in fresh medium with (treated) 
or without (control) assay samples. At the end of 
the culture period, the 45Ca was counted separately 
in the medium and in the bone and the ratio of the 
treated to the control was calculated. 
2.5. Statistical analysis 
Results were expressed as the mean + SD of at 
least 4 independent sets of experiments. In each ex- 
periment, triplicate assays were performed. The 
statistical significance of the difference between 
the control and the experimental group was ana- 
lysed by Student’s t-test. 
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Fig.1. Structures of lcu-(OH)D3, la,25-(OH)z&, 20-oxa-lcu-(OH)D3, 20-oxa-lcu,25-(OH)2D3, 22-oxa-la-(OH)& and 
22-oxa-la,25-(OH)2D3. 
3. RESULTS 
First, in an attempt to screen biological activity 
of the four oxa compounds, their differentiation- 
inducing activity was compared with that of 
la,25-(OH)zD3 and lcu-(OH)DJ, using the induc- 
tion of NBT-reducing activity in HL-60 cells. Fig.2 
shows their dose-response curves. 22-Oxa-la,25 
(OHhD3 had the highest activity, followed by 
l&,25-(OH)~DJ, 20-oxa-lcu,25-(OH)zDx, 22-oxa- 
lcu-(OH)D3, lcu-(OH)Ds and 20-oxa-la-(OH)D3, 
in that order. As expected, the vitamin D3 deriva- 
tives with a hydroxyl function at position 25 in- 
duced NBT-reducing activity more potently than 
the corresponding compounds without a hydroxyl 
function at position 25. It is also clear that the 
compounds with oxygen substituted at position 22 
exhibit a stronger NBT-reducing activity, and the 
compounds with oxygen substituted at position 20 
are weaker than the corresponding original com- 
pounds (la,25-(OH)2D3 or la-(OH)D3). 
To examine further the differentiation-inducing 
activity of 22-oxa-la,25-(OH)2D3, its activity to 
suppress growth and to induce differentiation was 
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Fig.2. Relative potency of the oxa compounds of vitamin D3 in inducing NBT-reducing activity in HL-60 cells. ICU- 
(OH)D3 (A), lcu,25-(OH)~D3 (A), 20-oxa-h-(OH)D3 (O), 20-oxa-h,25-(OH)zD3 (m), 22-oxa-la-(OH)DJ (0), and 
22-oxa-la,25(OH)zD3 (0). 
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assessed in WEHI- cells (fig.3). 22-Oxa- 
luu,25-(OH)2Dj was about IO-times more potent 
than 1~,25-(OH)ZDJ in suppressing proliferation 
(A) and in inducing phagocytic activity (B). The 
oxa compound induced both growth inhibition and 
appearance of phagocytic activity as fast as, or 
even faster than, lcu,25-(OH)zD3 did (C and D). 
In contrast, 22-oxa-lru,25-(OH)zD3 first induced 
the release of 45Ca from prelabeled fetal bone at as 
high as 4.8 nM, whereas la,25-(OH)2D3 induced a 
significant bone-resorbing activity at as low as 
0.12 nM (table 1). The in vitro bone-resorbing ac- 
tivity of 22-oxa-1@,25-(OH)2D3 was estimated to 
be only l/50-1/100 that of lcu,25-(OH)zD3. 
o”O.01 0.1 1 10 
Concentration (nM) Time (hr) 
Fig.3. Comparison of the growth-inhibiting activity and 
the differentiation-inducing activity of 22-oxa-la,25- 
(OH)zD3 (0) and lc1,25-(OH)2D3 (A). (A) Dose-re- 
sponse curves in growth inhibition and (B) their time 
course change. (C) Dose-response curves in the ap- 
pearance of phagocytic activity and (D) their time course 
change. The dose-response effect was measured on day 
3, and the time course effect was measured at 10 nM. 
Data are the mean + SD of 6 independent sets of 
experiments. Significantly different from the lcu,25- 
(OH)zDj group on each concentration or each time point 
(*, p < 0.05; **, p < 0.01; ***, p < 0.001). 
Table 1 
Effect of 22-oxa-lcu,25-(OH)2D3 and lcu,25-(OH)zDs on 
the release of 45Ca from prelabeled fetal mouse calvaria 
Concentration 45Ca release (T/C ratio) 
of vitamin D3 
compounds 22-oxa-la,25- 1~,25-(OH)zD3 
(nM) (OH)& 
0.0 0.94 + 0.14 (11) 
0.12 1.10 + 0.36 (4) 1.50 f 0.29* (10) 
0.60 _ 2.02 Z!I 0.61* (4) 
1.20 1.22 + 0.11 (11) 2.52 k 0.33** (11) 
4.80 1.37 + 0.10* (4) - 
12.00 1.75 f 0.26* (11) - 
Data are the mean +_ SD (number of experiments). 
Significantly different from control (* p < 0.05; ** p < 
0.01) 
4. DISCUSSION 
The present study indicates that the 
differentiation-inducing activity of vitamin D com- 
pounds could be separated structurally from their 
bone-resorbing activity, at least in vitro. The 
differentiation-inducing activity includes suppres- 
sion of proliferation and induction of differentia- 
tion of several hematopoietic cells, whereas the 
bone-resorbing activity is induced by promoting 
osteoclast formation from their progenitors and by 
somehow activating resting osteoclasts [ 111. 
It is possible to postulate several reasons why 
22-oxa-1a,25-(OH)2D3 exhibited an activity more 
potent than lcu,25-(OH)zD3 in suppressing growth 
of WEHI- cells and in inducing differentiation of 
both HL-60 and WEHI- cells without exhibiting 
significant bone-resorbing activity. It is known 
that the physicochemical properties of 22-oxa- 
lc~,25-(OH)~D3 are different from those of la,25- 
(OH)zD3. For instance, the distance of the side 
chain (between CX, and C25) of the two compounds 
is different: 5.15 A in la,25-(OH)2D3 and 4.96 A 
in 22-oxa-lcu,25-(OH)2D3. The rotation of the side 
chain is more strictly limited in 22-oxa-la,25- 
(OH)2D3 than in la,25-(OH)zD3, because of the 
presence of the oxygen atom at position 22 in the 
former. Furthermore, 22-oxa-la,25-(OH)2D3 was 
more polar than 1@,25-(OH1)2D3 (not shown). 
These differences in the physicochemical proper- 
ties appear to be involved in the separation of the 
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differentiation-inducing activity from the bone- 
resorbing activity of vitamin D compounds. 
Wovkulich et al. [6] and Ostrem et al. [7] have also 
independently pointed out the importance of the 
modification of the side chain structure, par- 
ticularly at positions Czz-Cz4, of vitamin D com- 
pounds in separating the two activities. 
It is well known that vitamin D compounds ex- 
hibit their biological activities by a receptor- 
mediated mechanism. Very recently, McDonnell et 
al. [12] succeeded in the molecular cloning of com- 
plementary DNA encoding the avian intestinal 
receptor for lcu,25-(OH)zD3. The molecular struc- 
ture of the la,25(OH)zDj receptors in tissues 
other than intestine, however, has not been iden- 
tified. There may be a qualitative tissue difference 
in the la,25-(OH)2D3 receptors between myeloid 
leukemia cells and bone cells. If so, it may become 
possible to separate the differentiation-inducing 
activity of vitamin D compounds from their hyper- 
calcemic action. 
Another important point is that the binding af- 
finity of vitamin D compounds for lau,25-(OH)2Dj 
receptors is not necessarily correlated with the 
potency of their biological activity. The binding af- 
finity of 22-oxa-lcu,25-(OH)zD3 for the la,25- 
(OH)2D3 receptor in HL-60 cells was weaker than 
that of lcu,25-(OH)zD3 (not shown), whereas the 
former compound exhibited a more potent activity 
than the latter in inducing NBT-reducing activity 
in HL-60 cells (fig.2). This suggests that factors 
other than the binding affinity for the receptor, 
such as stability, cellular uptake and intracellular 
metabolism of vitamin D compounds, are also im- 
portant in separating the differentiation-inducing 
activity from the hypercalcemic action. 
It is particularly important to determine whether 
22-oxa-lcu,25-(OH)2D3 exhibits potent differentia- 
tion-inducing activity in vivo without inducing 
hypercalcemia. To evaluate this, the in vivo dif- 
ferences in the differentiation-inducing activity 
and hypercalcemic action of 22-oxa-la,25- 
(OH)ZD~ and l~u,25-(OH)zD3, and their metab- 
olism and tissue distribution have to be examined. 
These are currently under investigation in our 
laboratories. 
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